Drug Profile

CDR 202

Alternative Names: BI-771716; CDR-202

Latest Information Update: 24 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CDR-Life
Developer Boehringer Ingelheim
Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Dry macular degeneration

Most Recent Events

06 Jan 2025 Phase-II clinical trials in Dry macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT06722157)
05 Sep 2024 Boehringer Ingelheim plans a phase II trial for Dry macular degeneration in USA and Puerto Rico (Intravitreal) in December 2024 (NCT06722157)
05 Sep 2024 Adverse events data from a phase I trial in dry macular degeneration released by Boehringer Ingelheim

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com